|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Colin Chen | Hank Chen | Chang, Lei Yao | 02-26518669 | 2F., No. 316, Chongyang Rd.,Nangang Dist., Taipei City 11573, Taiwan | 2019/03/26 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | BioLASCO Taiwan Co., Ltd. is a professional provider producing international standard SPF (Specific Pathogen Free) mice and rats in Taiwan. We also help customers to use animal holding service to produce high value special animal models. In addition, for the need of housing and experiments, the imported well-known laboratory equipment, materials and testing reagent are provided. Moreover, we provide interpretation of pathological & toxicological results. the biomedical and life-science community can have a precise outcome. The main business lines are listed as below: A: International standard SPF mice and rats B: Imported animal services C: Equipment, instruments, testing reagent and materials for housing and experiments. D: Interpretation of pathological & toxicological results E: Consultant services for animal projects and vivarium design |
Market Information ( 2024/04/24 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
8 | 36.40 | 35.30 | 35.80 | 0.55 | 8 | .00 | N/A | N/A | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/25) |
TPEx measures adopted (2024/04/25) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |